导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.75% | 1558/4773 |
| 近一周 | -1.14% | 1732/5465 |
| 近一月 | 0.65% | 478/5421 |
| 近一季 | 0.33% | 938/5231 |
| 近半年 | 0.18% | 1353/4920 |
| 近一年 | 7.20% | 1504/4394 |
| 近两年 | 56.81% | 1320/2954 |
| 近三年 | 43.88% | 672/2253 |
| 成立以来 | 53.35% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.61% 2384/4961 |
4.11% 2923/5312 |
- - |
- - |
| 2025 | 22.47% 1970/4813 |
0.49% 1832/3635 |
4.96% 674/4076 |
12.33% 3081/4524 |
3.36% 688/4813 |
| 2024 | 17.59% 671/3463 |
3.46% 565/2808 |
-0.66% 815/3014 |
13.71% 2125/3129 |
0.62% 1188/3463 |
| 2023 | -0.28% 446/2656 |
4.42% 960/2280 |
-1.48% 495/2385 |
0.32% 372/2515 |
-3.37% 671/2655 |
| 2022 | -7.27% 141/2207 |
-9.21% 314/1919 |
6.01% 789/2016 |
-8.49% 203/2113 |
5.28% 476/2208 |
| 2021 | 10.57% 429/1822 |
-0.35% 358/1255 |
4.86% 840/1330 |
0.10% 470/1466 |
5.71% 273/1822 |
| 2020 | - - |
- - |
- - |
- - |
5.98% 768/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰上证综合交易ETF VS. 长安沪深300非周期A(740101) |